Search
pexidartinib (Turalio)
Indications:
- tenosynovial giant cell tumor
Dosage:
- 400 mg (2 capsules) orally twice daily on an empty stomach
Capsules: 200 mg
Adverse effects:
- increased serum lactate dehydrogenase
- increased serum transaminases, serum alkaline phosphatase
- hypophosphatemia
- hair color changes
- increased serum cholesterol
- neutropenia, lymphopenia, anemia
- eye edema
- rash
- dysgeusia
* boxed warning: potentially fatal hepatotoxicity
Mechanism of action:
- tyrosine kinase inhibitor, targeting
- colony stimulating factor 1 receptor (CSF1R),
- KIT proto-oncogene receptor tyrosine kinase (KIT)
- FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation.
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- PubChem: 25151352
- FDA News Release. August 2, 2019
FDA approves pexidartinib for tenosynovial giant cell tumor.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pexidartinib-tenosynovial-giant-cell-tumor